201 related articles for article (PubMed ID: 31190182)
1. Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1-2N0M0 lung cancer patients staged by PET/CT.
Ouyang ML; Xia HW; Xu MM; Lin J; Wang LL; Zheng XW; Tang K
Ann Nucl Med; 2019 Sep; 33(9):671-680. PubMed ID: 31190182
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A
Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Occult Lymph Node Metastasis Using Tumor-to-Blood Standardized Uptake Ratio and Metabolic Parameters in Clinical N0 Lung Adenocarcinoma.
Ouyang ML; Tang K; Xu MM; Lin J; Li TC; Zheng XW
Clin Nucl Med; 2018 Oct; 43(10):715-720. PubMed ID: 30106864
[TBL] [Abstract][Full Text] [Related]
4. Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.
Kim DH; Song BI; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2051-7. PubMed ID: 24990401
[TBL] [Abstract][Full Text] [Related]
5. Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non-small cell lung cancer patients.
Shi YM; Niu R; Shao XL; Zhang FF; Shao XN; Wang JF; Wang XS; Liu B; Yu WJ; Wang YT
Nucl Med Commun; 2020 May; 41(5):459-468. PubMed ID: 32187163
[TBL] [Abstract][Full Text] [Related]
6. The value on SUV-derived parameters assessed on
Liao X; Liu M; Li S; Huang W; Guo C; Liu J; Xiong Y; Zhang J; Fan Y; Wang R
BMC Med Imaging; 2023 Apr; 23(1):49. PubMed ID: 37020286
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic.
Li L; Ren S; Zhang Y; Guan Y; Zhao J; Liu J; Wang Q; Chen G; Chen H; Xiang J; Fu X
Lung Cancer; 2013 Aug; 81(2):213-7. PubMed ID: 23664030
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non-Small Cell Lung Cancer.
Kim DH; Jung JH; Son SH; Kim CY; Hong CM; Oh JR; Jeong SY; Lee SW; Lee J; Ahn BC
Clin Nucl Med; 2015 Sep; 40(9):708-14. PubMed ID: 26098287
[TBL] [Abstract][Full Text] [Related]
9. Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer.
Park SY; Yoon JK; Park KJ; Lee SJ
Cancer Imaging; 2015 Dec; 15():21. PubMed ID: 26694918
[TBL] [Abstract][Full Text] [Related]
10. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
Li C; Tian Y; Shen Y; Wen B; He Y
AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465
[No Abstract] [Full Text] [Related]
11. An Investigation of the Relationship Between
Kandemir O; Demir F
Curr Radiopharm; 2024; 17(1):111-116. PubMed ID: 37644744
[TBL] [Abstract][Full Text] [Related]
12. Determination of regional lymph node status using (18)F-FDG PET/CT parameters in oesophageal cancer patients: comparison of SUV, volumetric parameters and intratumoral heterogeneity.
Kim SJ; Pak K; Chang S
Br J Radiol; 2016; 89(1058):20150673. PubMed ID: 26607643
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
[TBL] [Abstract][Full Text] [Related]
14. Significance of
Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH
Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Kaseda K; Asakura K; Kazama A; Ozawa Y
World J Surg; 2016 Dec; 40(12):2976-2983. PubMed ID: 27456499
[TBL] [Abstract][Full Text] [Related]
16. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma.
Moon SH; Kim HS; Hyun SH; Choi YS; Zo JI; Shim YM; Lee KH; Kim BT; Choi JY
J Nucl Med; 2014 May; 55(5):743-8. PubMed ID: 24700884
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
19. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET/CT in mediastinal lymph node metastasis of non-small cell lung cancer.
Hua J; Li L; Liu L; Liu Q; Liu Y; Chen X
Nucl Med Commun; 2021 Nov; 42(11):1247-1253. PubMed ID: 34269750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
